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 Introduction 
 Dementia is associated with a higher rate of comorbid-
ity, poor functional status and increased mortality  [1–3] . 
The emotional and financial burden of dementia and
Alzheimer’s disease (AD) on society will increase in the 
next decades  [4] . The clinical assessment of dementia in 
specialized centers, such as memory clinics, has led to 
earlier diagnosis and has stimulated the search for poten-
tial therapeutic agents and preventative strategies  [5] . The 
American Academy of Neurology recommends screen-
ing for vitamin B 12 deficiency and hypothyroidism in pa-
tients with dementia  [6] . In the Dutch consensus, screen-
ing for folate and vitamin B 1 , B 6 and B 12 deficiency is rec-
ommended  [7] .
 Recent insights suggest that vitamin D, mostly known 
for its effects on calcium and bone metabolism, may have 
neuroprotective functions and could be important for 
preserving cognitive functions via several different
mechanisms  [8] .
 Vitamin D is a secosteroid hormone. The term vita-
min D refers to the inert precursors vitamin D 3 (cholecal-
ciferol) and vitamin D 2 (ergocalciferol). The precursors 
are either formed in the skin after exposure to sunlight 
or derived from dietary sources. In the liver, the precur-
sors are converted to 25-hydroxyvitamin D 3 [25-(OH)D 3 ]. 
In the kidney, 25-(OH)D 3 is hydroxylated to 1,25-dihy-
droxyvitamin D 3 [1,25(OH) 2 D 3 ], the most active vitamin 
D metabolite  [9] . The serum 25-(OH)D 3 levels are gener-
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 Abstract 
 Background/Aims: Recent studies suggest that vitamin D 
metabolites may be important for preserving cognitive 
function via specific neuroprotective effects. No large stud-
ies have examined the association between vitamin D status 
and cognition.  Methods: In this cross-sectional study, we
analyzed the serum 25-hydroxyvitamin D 3 levels and Mini-
Mental State Examination (MMSE) test scores of 225 older 
outpatients who were diagnosed as having probable Alz-
heimer’s disease (AD). In addition to the 25-hydroxyvitamin 
D 3 levels, we analyzed the serum vitamin B 1 , B 6 and B 12 levels. 
 Results: An association was found between MMSE test 
scores and serum 25-hydroxyvitamin D 3 levels, with a   -co-
efficient of 0.05 (p = 0.01). Vitamin-D-sufficient patients had 
significantly higher MMSE scores as compared to vitamin-D-
insufficient ones. No association was found with the other 
serum vitamin levels.  Conclusions: These data support the 
idea that a relationship exists between vitamin D status and 
cognition in patients with probable AD. However, given the 
cross-sectional design of this study, no causality can be con-
cluded. Further prospective studies are needed to specify 
the contribution of vitamin D status to the onset and course 
of cognitive decline and AD.  Copyright © 2008 S. Karger AG, Basel 
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ally used to determine the vitamin D status of an indi-
vidual. Serum 25-(OH)D 3 levels of  1 50 nmol/l are gener-
ally defined as sufficient, although recent reports suggest 
that a serum 25-(OH)D 3 level  1 75 nmol/l may be prefer-
able for optimal health  [10] .
 The vitamin D metabolites exert their effects via the 
vitamin D receptor (VDR). Recently, it has been shown 
that neurons also express the VDR, which makes them a 
potential target tissue for vitamin D metabolites  [11] . The 
VDR is abundantly expressed in regions frequently af-
fected in AD such as the hypothalamus, substantia nigra, 
cortex and hippocampus. The importance of a sufficient 
vitamin D status for cognitive functioning in humans is 
not known. A recent study reported an association be-
tween serum 25-(OH)D 3 levels and cognitive functioning 
in a relatively small cohort of patients referred to a mem-
ory clinic  [12] .
 Because of these new insights, we examined the rela-
tionship between vitamin D status and cognitive func-
tion in a cohort of older patients with probable AD in our 
memory clinic. We also analyzed the serum levels of vi-
tamin B 1 , B 6 and B 12 , as screening for deficiencies in these 
vitamins is recommended in the clinical guidelines for 
the assessment of dementia.
 Methods 
 Patients 
 We included 962 consecutive patients who were referred to the 
geriatric outpatient clinic of the Erasmus University Medical 
Center. The patients were referred for a variety of reasons and un-
derwent a comprehensive geriatric assessment, including history 
and informant history, medication history, and physical and neu-
rological examination  [13] . They were asked to complete the 
Dutch version of the Mini-Mental State Examination (MMSE), 
with scores ranging from 0 points (poor cognitive functioning) to 
30 points (good cognitive functioning)  [14] . A consensus diagno-
sis of probable AD was obtained for 350 patients by a multidisci-
plinary memory clinic team including 2 geriatricians, a neurolo-
gist, a neuropsychologist and a psychiatrist  [15] . Seventy-seven 
percent also underwent a neuropsychological examination. After 
exclusion of patients taking any vitamin suppletion at the time of 
investigation, serum vitamin B 1 , B 6, B 12 and 25-(OH)D 3 levels 
were available for 225 out of 350 patients.
 The study was approved by the medical ethics committee of 
the Erasmus University Medical Center. Oral informed consent 
was obtained from the patients and their main caregiver.
 Dementia Diagnosis 
 The diagnosis of dementia was verified according to a stan-
dard protocol. Dementia was diagnosed with reference to the 
American Psychiatric Association’s criteria (DSM-IV)  [16] . The 
subdiagnosis of probable AD was based on the criteria of the 
NINCDS-ADRDA work group  [17] .
 Possible Cofactors 
 The serum 25-(OH)D 3 level strongly depends on sunlight ex-
posure and therefore data were collected on action radius and 
mobility as indicators for exposure to sunlight. The action radius 
was classified as going outside, being housebound or lying in bed 
 1 20 h per day. For scoring mobility we used a standardized mo-
bility scale assessing independence in walking, standing, trans-
fers in and out of bed/chair, and wheelchair use. The score for each 
of these items ranged from 0 points (complete independence) to 3 
or 4 points (complete dependence), with a maximum score of 14 
points  [18] . The total years of education were scored because both 
cognitive test performance and serum 25-(OH)D 3 level are influ-
enced by educational background  [19] .
 Blood Parameters 
 Blood samples were collected on the first visit to the outpatient 
clinic. The serum 25-(OH)D 3 levels were measured using a radio-
immunoassay (DiaSorin). The serum vitamin B 1 and B 6 levels 
were determined by high-performance liquid chromatography 
according to internal protocols of the clinical laboratory of the 
Erasmus University Medical Center. The serum vitamin B 12 levels 
were measured using a competitive protein-binding assay accord-
ing to internal protocols of the clinical laboratory of the Erasmus 
University Medical Center. All assessments were performed at the 
Erasmus University Medical Center.
 Statistical Analysis 
 The association between serum vitamin levels [25-(OH)D 3 , vi-
tamin B 1 , B 6 and B 12 ] and MMSE score (dependent variable) was 
investigated by linear regression. To adjust for possible confound-
ers, the models were adjusted for biologically plausible cofactors. 
These cofactors were age, gender, total mobility score, action ra-
dius, years of education and the vitamin levels not under investi-
gation. They were added to the model one by one as linear covari-
ables. Furthermore, the mean MMSE scores were compared be-
tween vitamin-D-insufficient and vitamin-D-replete patients. 
The cutoff point for defining vitamin D deficiency was set at a 
serum 25-(OH)D 3 level  ! 50 nmol/l  [20] . SPSS version 12.0 was 
used for statistical analysis (SPSS Inc., Chicago Ill., USA).
 Results 
 The characteristics of the population are shown in
 table 1 . The mean MMSE score was 19.7  8 6.3 points
and the mean serum 25-(OH)D 3 level was 45.4  8 22.8 
nmol/l. In this cohort 141 out of 225 individuals (63%) 
had a serum 25-(OH)D 3 level  ! 50 nmol/l and 197 out of 
225 (88%) had serum 25-(OH)D 3 levels  ! 75 nmol/l. The 
results of the regression analysis studying the association 
between serum 25-(OH)D 3 levels and MMSE scores are 
shown in  table 2 . A positive association between serum 
25-(OH)D 3 levels and MMSE score was observed with a 
  -coefficient of 0.08 (p  ! 0.001). This finding remained 
significant after adjustment for possible confounders
(  = 0.05; p = 0.01). The mean MMSE score in vitamin-
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D-deficient patients [25-(OH)D 3  ! 50 nmol/l] was 18.5  8 
6.0 points and that in vitamin-D-replete patients was 21.5 
 8 6.1 points (p = 0.003).  Figure 1 shows a scatter plot of 
the MMSE score versus serum 25-(OH)D 3 level.
 Both in the adjusted and unadjusted models no sig-
nificant associations were observed between serum vita-
min B 1 , B 6 and B 12 levels and MMSE score  ( table 2 ).
 Discussion 
 In the present study, performed in a geriatric outpa-
tient population, we tested the hypothesis that the serum 
25-(OH)D 3 levels are related to the level of cognitive func-
tioning in patients with probable AD. We found an asso-
ciation between MMSE scores and serum 25-(OH)D 3 lev-
els. No link was observed between MMSE scores and se-
rum vitamin B 1 , B 6 or B 12 levels. This may be due to the 
fact that the mean serum vitamin B 1 , B 6 and B 12 levels 
were within the normal range.
 The high prevalence of vitamin D deficiency in our 
patients is in accordance with other reports both from the 
Netherlands and abroad  [21, 22] .
 Our study is, to the best of our knowledge, the largest 
to date examining the association between serum 25-
(OH)D 3 level and cognition in a cohort of older AD pa-
tients. The results are in line with a previous study on the 
association between serum 25-(OH)D 3 levels and cogni-
tive functioning  [12] .
 Given the cross-sectional design of this study, the as-
sociation between vitamin D status and MMSE scores 
can be interpreted in several ways. First, vitamin D defi-
ciency may lead to a gradual decline in cognitive func-
tions. Data, mostly from ex vivo and animal studies, sug-
gest that vitamin D metabolites may have protective ef-
fects on neurons or neurotransmitter pathways which 
could benefit cognition. It has been proposed that vita-
min D metabolites exert their protective effects on the 
central nervous system by stimulating the production of 
neurotrophins or by inhibiting the production of induc-
ible nitric oxide  [8] . A positive effect of 1,25-(OH) 2 D 3 on 
the acetylcholine pathway has also been reported  [23] . 
Recent studies suggest that 1,25-(OH) 2 D 3 may also de-
Table 1. Characteristics of study population (n = 225)
Characteristics Mean 8 SD Range
Age, years 77.687.3 60–94
Female gender 147 (65%) –
MMSE score, points 19.786.3 1–30
Mobility score, points 1.382.8 0–14
Education, years 8.883.1 3–20
Serum 25-(OH)D3, nmol/l
(normal range: >50) 45.4822.8 5–106
Serum vitamin B1, nmol/l
(normal range: 70–140) 105.1826.3 47–167
Serum vitamin B6, nmol/l
(normal range: 46–126) 63.3844.5 26–151
Serum vitamin B12, pmol/l
(normal range: 145–637) 304.58137.7 60–755
SD = Standard deviation.
Table 2. Linear regression -coefficients describing the associa-






p value Adjusted 
-coefficient
p value
Serum 25-(OH)D3 0.08 <0.001 0.05 0.01
Serum vitamin B1 0.03 0.1 0.02 0.3
Serum vitamin B6 0.003 0.8 0.005 0.6
Serum vitamin B12 –0.001 0.9 –0.002 0.5
Adjusted: age, sex, mobility score, action radius, total years of 
























 Fig. 1. Scatter plot of the MMSE score versus serum 25-(OH)D 3 
level. 
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crease the production of proinflammatory cytokines like 
tumor necrosis factor   . Tumor necrosis factor   is 
thought to play a pathogenic role in neurodegenerative 
disorders, such as AD and Parkinson’s disease  [24, 25] .
 Conversely, cognitive decline may cause vitamin D de-
ficiency. It has been shown that AD can lead to malnutri-
tion, which in turn could contribute to the development 
of vitamin D deficiency  [26] . In addition, exposure to 
sunlight might decrease due to behavioral problems in 
AD, such as apathy and inertia, leading to more time be-
ing spent indoors  [27] .
 A reduction in VDR expression in different layers of 
the hippocampus in patients with AD has been reported 
 [28] . The hippocampus is the most typical part of the 
brain involved in AD. The regulators of VDR expression 
in the central nervous system are still largely unknown. 
In other cell types such as muscle cells, a decreased ex-
pression of the VDR, independent of serum vitamin D 
level, has been described with aging  [29] . However, con-
tradictory results, which question the role of vitamin D 
metabolites in the preservation of cognitive function, 
come from a recent animal study that showed muscular 
and motor impairments, but no impairments in cogni-
tion, in VDR knockout mice compared to wild-type mice 
 [30] .
 Our study has some limitations. First, because of the 
cross-sectional design, no causality can be concluded. 
However, it seems worthwhile to gain more insight into 
the association between vitamin D deficiency and cogni-
tive impairment, as supplementation of vitamin D might 
be an inexpensive and safe intervention  [31] .
 Second, the MMSE is a crude measure of cognitive 
functions and fluctuations in cognition could have been 
missed  [32] . However, AD diagnosis in our patients was 
verified by neuropsychological testing and based on a 
thorough multidisciplinary diagnostic process.
 In view of the high prevalence of vitamin D deficiency 
in our rather mobile outpatients, our study supports the 
recommendations for preventative vitamin D supple-
mentation in older people at risk  [22] .
 In conclusion, the results of the present study suggest 
that an association exists between vitamin D status and 
cognitive functioning in AD. Further prospective studies 
with a long follow-up period and with more elaborate 
data on cognitive function and cognitive test perfor-
mance are needed to specify the possible contribution of 
vitamin D deficiency to the onset and course of cognitive 
decline and AD. In the meantime, we should continue to 
recognize that vitamin D deficiency is prevalent in older 
persons. Quite apart from the consideration that vitamin 
D metabolites may have specific neuroprotective effects, 
the need to identify and treat comorbid conditions in AD 
patients remains unchanged  [33] .
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